Transcranial Magnetic Stimulation (TMS) treatment study in auditory verbal hallucinations

Transcranial Magnetic Stimulation (TMS) treatment study in auditory verbal hallucinations: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN61109178

Enrollment

Registered

2012-02-10

Start date

2008-12-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia or schizoaffective disorder, medication resistant auditory hallucinations Mental and Behavioural Disorders Schizophrenia

Interventions

1. Theta Burst transcranial magnetic stimulation (TBS group) 2. 1Hz transcranial magnetic stimulation and 3. Control group (treatment as usual) A custom TMS stimulator (MagPro R 100, Medtronic Func

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of schizophrenia or schizoaffective disorder according to ICD-10 2. Medication-resistant auditory verbal hallucinations 3. 18?65-years of age, and right-handed 4. Therapy refractoriness is defined as non response to at least 2 antipsychotic treatments in common dosages, each administered for at least 8 weeks

Exclusion criteria

Exclusion criteria: 1. History of epileptic seizures 2. Signs of elevated neuronal activity by electroencephalography (EEG) 3. Magnetic resonance (MR) contraindications, and 4. Medical disorders other than schizophrenia or schizoaffective disorder

Design outcomes

Primary

Measure	Time frame
1. Psychopathology rates: 1.1. Positive and negative symtpom scale 1.2. Psychotic Symptom Rating Scales (PSYRATS) 1.3. Auditory hallucination rating scale 2. Cerebral blood flow as measured by magnetic resonance arterial spin labeling	—

Secondary

Measure	Time frame
1. Comparison of conventionally used 10-20 EEG coil placement approach with a frameless steretactic neuronavigation system to functionally defined (fMRI) target area 2. TMS effects on electroencephalography measures 3. Assessment of side effects	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026